Show simple item record

Files in this item


Item metadata

dc.contributor.authorSiriyong, Thanyaluck
dc.contributor.authorOntong, Julalak Chorachoo
dc.contributor.authorLeejae, Sukanlaya
dc.contributor.authorSuwalak, Sakol
dc.contributor.authorCoote, Peter John
dc.contributor.authorVoravuthikunchai, Supayang Piyawan
dc.identifier.citationSiriyong , T , Ontong , J C , Leejae , S , Suwalak , S , Coote , P J & Voravuthikunchai , S P 2020 , ' In vivo safety assessment of rhodomyrtone, a potent compound, from Rhodomyrtus tomentosa leaf extract ' , Toxicology Reports , vol. 7 , pp. 919-924 .
dc.identifier.otherPURE: 269483823
dc.identifier.otherPURE UUID: 4ec4fcfd-2058-4737-8d44-ecd6301fbeec
dc.identifier.otherRIS: urn:5255FFC96ED826C927063AE0DA77AF9C
dc.identifier.otherORCID: /0000-0001-5190-805X/work/78527892
dc.identifier.otherScopus: 85088938940
dc.identifier.otherWOS: 000604359600007
dc.descriptionThis research was funded by the Thailand Research Fund Senior Research Scholar (Grant number RTA6180006).en
dc.description.abstractBackground Rhodomyrtus tomentosa (Aiton) Hassk. has been traditionally used to relieve various diseases. Rhodomyrtone, a bioactive acylphloroglucinol compound isolated from the leaves of Rhodomyrtus tomentosa, has been scientifically evidenced as a potential antibacterial agent. This study aimed to assess safety of rhodomyrtone in both invertebrate and vertebrate models. Material and Methods Safety of rhodomyrtone was determined in an invertebrate model, Galleria mellonella as well as vertebrate models including zebrafish (Danio rerio) and murine. In addition, toxicity to human erythrocytes was also measured. Results Treatment of Galleria mellonella with rhodomyrtone at 100 mg/kg body weight up to four days showed no visible toxic effects (100 % survival). In zebrafish embryo model, at least 80 % survival of embryos was demonstrated when treated with rhodomyrtone at 0.5 μg/mL for three days. Prior to clinical trial, it is a prerequisite that rhodomyrtone has to be evaluated for its biocompatibility with human blood components. The results displayed that rhodomyrtone at 256 μg/mL did not cause any observable human erythrocyte haemolysis. Furthermore, preclinical assessment of rhodomyrtone formulation justified potential applications of rhodomyrtone in humans. Oral toxicity testing in a mouse model indicated the absence of systemic toxicity when the animals received up to 5000 mg/kg body weight of rhodomyrtone formulation for a period of fourteen days. Conclusions As the minimal inhibitory concentration of rhodomyrtone against most Gram-positive pathogens is 0.5−1 μg/mL, the results suggest that it should produce no toxic effects at concentrations used in human, thus support further development in pharmaceutical industries and public health applications.
dc.relation.ispartofToxicology Reportsen
dc.rightsCopyright © 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (
dc.subjectQH301 Biologyen
dc.subjectQR Microbiologyen
dc.titleIn vivo safety assessment of rhodomyrtone, a potent compound, from Rhodomyrtus tomentosa leaf extracten
dc.typeJournal articleen
dc.description.versionPublisher PDFen
dc.contributor.institutionUniversity of St Andrews.School of Biologyen
dc.contributor.institutionUniversity of St Andrews.Biomedical Sciences Research Complexen
dc.description.statusPeer revieweden

This item appears in the following Collection(s)

Show simple item record